ScoreWhy is Piramal Pharma Ltd ?
1
Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.83 times
- Poor long term growth as Net Sales has grown by an annual rate of 9.15% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.83 times
- The company has been able to generate a Return on Equity (avg) of 0.32% signifying low profitability per unit of shareholders funds
2
Negative results in Sep 25
- PBT LESS OI(Q) At Rs -111.78 cr has Fallen at -340.0% (vs previous 4Q average)
- PAT(Q) At Rs -99.22 cr has Fallen at -613.2% (vs previous 4Q average)
- NET SALES(Q) At Rs 2,043.72 cr has Fallen at -10.5% (vs previous 4Q average)
3
Below par performance in long term as well as near term
- Along with generating -31.12% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Piramal Pharma for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Piramal Pharma
-30.38%
-0.85
36.80%
Sensex
8.49%
0.44
11.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
7.96%
EBIT Growth (5y)
111.53%
EBIT to Interest (avg)
0.67
Debt to EBITDA (avg)
5.08
Net Debt to Equity (avg)
0.51
Sales to Capital Employed (avg)
0.64
Tax Ratio
100.00%
Dividend Payout Ratio
81.66%
Pledged Shares
0
Institutional Holding
45.35%
ROCE (avg)
2.65%
ROE (avg)
0.32%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
32
Price to Book Value
2.56
EV to EBIT
148.98
EV to EBITDA
24.27
EV to Capital Employed
2.04
EV to Sales
2.80
PEG Ratio
NA
Dividend Yield
0.06%
ROCE (Latest)
2.66%
ROE (Latest)
-0.55%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend1What is working for the Company
NO KEY POSITIVE TRIGGERS
-8What is not working for the Company
PBT LESS OI(Q)
At Rs -95.99 cr has Fallen at -2577.2% (vs previous 4Q average
PAT(Q)
At Rs -95.08 cr has Fallen at -755.0% (vs previous 4Q average
EPS(Q)
Lowest at Rs -1.03
Loading Valuation Snapshot...
Here's what is not working for Piramal Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs -95.99 cr has Fallen at -2577.2% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 3.88 CrMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs -95.08 cr has Fallen at -755.0% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs -11.12 CrMOJO Watch
Near term PAT trend is very negative
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Lowest at Rs -1.03
in the last five quartersMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (Rs)
